Filing Flows › Aquestive Therapeutics (AQST) › R&D spending
Aquestive Therapeutics (AQST) R&D spending by quarter
Aquestive Therapeutics' R&D spending was $4.3M in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 7 quarters it ranged from $3.2M (Q4 2025) to $5.4M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.3M | +7% | -6% |
| Q2 2026 | $4.0M | -6% | -3% |
| Q1 2026 | $4.2M | +32% | -22% |
| Q4 2025 | $3.2M | -29% | — |
| Q3 2025 | $4.5M | +10% | — |
| Q2 2025 | $4.1M | -23% | — |
| Q1 2025 | $5.4M | — | — |
Q3 2026 at a glance
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aquestive Therapeutics' R&D spending?
Aquestive Therapeutics' R&D spending was $4.3M in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Aquestive Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $3.2M (Q4 2025) to $5.4M (Q1 2025).
Q3 2026 results → · How Aquestive Therapeutics makes money →